Document is current
Any future updates will be listed below
-
Authors
Shi, Xiaolei
Day, Abderrahman http://orcid.org/0000-0002-3338-5088
Bergom, Hannah E.
Tape, Sydney
Baca, Sylvan C.
Sychev, Zoi E.
Larson, Gabrianne http://orcid.org/0000-0002-4831-715X
Bozicevich, Asha
Drake, Justin M.
Zorko, Nicholas http://orcid.org/0000-0001-7021-968X
Wang, Jinhua
Ryan, Charles J.
Antonarakis, Emmanuel S.
Hwang, Justin http://orcid.org/0000-0003-1686-7103
-
Funding
Funding for this research was provided by:
Ray of Light Foundation (University of Minnesota) Randy Shaver Cancer Research and Community Fund
- License Information
-
More Information
Article History
Received: 5 June 2022
Accepted: 14 October 2022
First Online: 2 November 2022
Competing interests
: E.S.A. is a paid consultant/advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, Eli Lilly, Bayer, AstraZeneca, Bristol Myers Squibb, ESSA, Clovis, Merck, Curium, Blue Earth Diagnostics, Foundation Medicine, Exact Sciences and Invitae; has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers Squibb, Constellation, Bayer, AstraZeneca, Clovis and Merck; and is the coinventor of a patented AR-V7 biomarker technology that has been licensed to Qiagen. J.M.D. has no conflicts relevant to this work. However, he holds equity in and serves as Chief Scientific Officer of Astrin Biosciences. This interest has been reviewed and managed by the University of Minnesota in accordance with its Conflict of Interest policies. None of these companies contributed to or directed any of the research reported in this article. N.Z. is an advisor/consultant for Caris. J.H. is a consultant/advisor to Caris Life Sciences and Astrin Biosciences. The remaining authors declare no competing interests.
